Skip to main content
SpringerLink
Log in

Prostacyclin and Its Stable Analogue Iloprost

  • Conference proceedings
  • © 1987

Overview

Editors:
  1. R. J. Gryglewski

    1. Department of Pharmacology, Copernicus Academy of Medicine, Cracow, Poland

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. G. Stock

    1. Cardiovascular Pharmacology, Schering AG, Berlin 65, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (33 papers)

  1. Front Matter

    Pages I-XV
    Download chapter PDF

  2. Introduction, Chemistry, Receptor Interaction and Platelet Mechanisms

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. The Impact of Prostacyclin Studies on the Development of Its Stable Analogues

      • R. J. Gryglewski
      Pages 3-15

    3. Chemistry of Stable Prostacyclin Analogues: Synthesis of Iloprost

      • W. Skuballa, B. Radüchel, H. Vorbrüggen
      Pages 17-24

    4. Prostaglandins, Thromboxanes and Platelet Function

      • G. de Gaetano, V. Bertelé, C. Cerletti
      Pages 25-37

    5. Effects of Iloprost on Platelet Activation In Vitro

      • C.-S. Stürzebecher, W. Losert
      Pages 39-45

    6. In Vitro Effects of Iloprost on Platelet Aggregation in Normal and Hypercholesterolemia Subjects

      • E. Tremoli, P. Maderna, L. Mannucci, S. Colli, R. Paoletti
      Pages 47-51

    7. Desensitization of Iloprost or Prostacyclin Responsiveness

      • J. MacDermot, U. Alt, P. J. Leigh, P. K. Morris, A. J. Wilkins, M. J. Brown et al.
      Pages 53-56

    8. Resistance of Platelets to Prostacyclin

      • R. V. Manrique, V. Manrique
      Pages 57-63

    9. Preliminary Comparison of the Effects of Iloprost, Prostacyclin (PGI2) and Prostaglandin E1 (PGE1) on Human Platelet Function

      • C. A. Fisher, H. J. Reiser, V. P. Addonizio
      Pages 65-68

    10. Laboratory Investigations of Potential Heparin — Iloprost Interactions

      • S. J. Machin, D. A. Yardumain, K. O’Flynn, D. C. Linch
      Pages 69-79

    11. Antithrombotic Profile of Iloprost in Experimental Models of Arterial and Venous Thrombosis

      • W. Witt, B. Baldus, B. Müller
      Pages 81-90

    12. Monitoring of Effectiveness of Prostaglandin Therapy in Humans

      • H. Sinzinger
      Pages 91-96

    13. Effect of Iloprost (ZK 36374) on White Cell Behavior

      • J. J. F. Belch, A. Saniabadi, R. Dickson, R. D. Sturrock, C. D. Forbes
      Pages 97-102

  3. Back Matter

    Pages 103-112
    Download chapter PDF

  4. Cardiovascular Pharmacology, Tissue Protection and Effects on Prostaglandin Synthesis

    1. Front Matter

      Pages 113-113
      Download chapter PDF

    2. Eicosanoid Expression of Vascular Sexual Dimorphism

      • C. Cunard, Y. Maddox, J. Falcon, M. Ridinger, P. W. Ramwell
      Pages 115-121

    3. Profile of Generation of Eicosanoids by Blood Vessels and the Heart

      • Th. Simmet, B. A. Peskar
      Pages 123-128

    4. Studies on Vasorelaxant Effects and Mechanisms of Iloprost in Isolated Preparations

      • G. Schröder, R. Beckmann, E. Schillinger
      Pages 129-137

    5. Effects of Iloprost Treatment in the Rat on Prostacyclin Release from Isolated Aortas

      • I. Masi, E. Giani, C. Mosconi, C. Galli
      Pages 139-142
Back to top

Keywords

About this book

Ten years after the discovery of prostacyclin, our knowledge of its biochemical mode of action, pharmacological properties, pathophysiological significance and therapeutic applications is ever expanding. Prostacyclin is both complex and unique as demonstrated by its unusual feature of being chemically and meta­ bolically unstable when compared to other prostanoids and known amine or peptide mediators. Although physiologically essential, the chemical instability of prostacyclin poses a serious drawback in laboratory and clinical studies. It is one of the genuine objectives of pharmaceutical research to supply synthetic compounds which overcome the inherent drawbacks - considering investigational and therapeutic use - of endogenous compounds. Whereas metabolic instability in certain cases could be of advantage, chemical instability definitely is not. With Iloprost, a molecule has been designed which - according to all data so far available - pertains high receptor affinity, metabolic instability (clinically this equates with a fine control of Iloprost's effects) while chemical stability has been achieved. By virtue of these characteristics Iloprost can be considered as one step towards specific interaction within the arachidonic acid cascade, namely the prostacyclin receptor. The aim of the symposium was to provide a critical experimental appraisal concerning the biochemical mode of action and pharmacological properties of prostacyclin and Iloprost.

Editors and Affiliations

  • Department of Pharmacology, Copernicus Academy of Medicine, Cracow, Poland

    R. J. Gryglewski

  • Cardiovascular Pharmacology, Schering AG, Berlin 65, Germany

    G. Stock

Bibliographic Information

  • Book Title: Prostacyclin and Its Stable Analogue Iloprost

  • Editors: R. J. Gryglewski, G. Stock

  • DOI: https://doi.org/10.1007/978-3-642-71499-3

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin Heidelberg 1987

  • Softcover ISBN: 978-3-642-71501-3Due: 23 November 2011

  • eBook ISBN: 978-3-642-71499-3Published: 06 December 2012

  • Edition Number: 1

  • Number of Pages: XV, 314

  • Topics: Cardiology, Pharmacology/Toxicology

Publish with us

Policies and ethics

Back to top

Search

Navigation